GlassScriptPhysician profile
Neil A Thierry
NPI 1548271596
$3,709.95
in general payments reported to CMS, 2019-2025
15 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2021: $227 · 2022: $231 · 2023: $497 · 2024: $772 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $829.86 | 2019-2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $473.46 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $415.80 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $334.18 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $298.30 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $295.22 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $239.59 | 2024-2025 | Cobenfy |
| Abbvie INC. | $225.91 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $187.71 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Tris Pharma INC | $143.64 | 2024-2025 | Onyda Xr |
| Indivior INC. | $96.68 | 2023-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $82.88 | 2024-2025 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $69.92 | 2024-2025 | Qelbree |
| Neuronetics, INC. | $11.48 | 2019 | |
| Corium, LLC | $5.32 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Thierry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.